ArticleCancer discovery2025
Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers.
Abstract read
In one paragraph
Article in Cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Multi-cancer early detection tests for general population screening: a systematic literature review.Health technology assessment (Winchester, England) · 2025Pooled it
- Systemic health impact of cancer-associated extracellular vesicles and particles.Nature reviews. Cancer · 2026Review
- Development and validation of a serum peptidomic signature for early detection of asymptomatic ovarian cancer: A multi-center prospective study.Cell reports. Medicine · 2026Article
- Liquid biopsy: a new window on the BRCA genes.ESMO open · 2026Review
- Nicotinamide mononucleotide potentiates the anti-tumor efficacy of CAR-NK cell therapy targeting MSLN in ovarian cancer.Cancer gene therapy · 2026Article
- Advancing the applications of liquid biopsies in oncology.Nature reviews. Genetics · 2026Review
- Molecular Response Assessment From Circulating Tumor DNA in Patients With Ovarian Cancer Treated With the WEE1 Inhibitor Azenosertib.JCO precision oncology · 2026Article
- Rethinking ovarian cancer III: the past decade and future directions.Nature reviews. Cancer · 2026Review
- The cervico-vaginal DNA methylation WID-qEC test: An epigenetic marker associated with ovarian cancer in the absence of endometrial and cervical cancer.International journal of cancer · 2026Article
- Circulating Lipid Traits and Ovarian Cancer Risk: A Systematic Review and Meta-Analysis with Mendelian Randomization Integration.Metabolites · 2026Review
- Article
- Harnessing genomics for early cancer detection, risk stratification and prevention.Nature genetics · 2026Review
- Cell-free DNA fragmentomes for noninvasive detection of liver cirrhosis and other diseases.Science translational medicine · 2026Article
- Study on the expression level of folate receptor γ in thyroid cancer and its association with clinicopathological characteristics.Oncology letters · 2026Article
- Dual Targeting of Mutant p53 and SNRPD2 via Engineered Exosomes Modulates Alternative Splicing to Suppress Ovarian Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- High-Grade Serous Ovarian Carcinoma in the Genomics Era: Current Applications, Challenges and Future Directions.International journal of molecular sciences · 2026Review
- The best from both disciplines: integrating human and microbial signatures from whole genome sequencing to advance cancer diagnostics.mSystems · 2026Review
- Circulating extracellular vesicle DNA (EV-DNA) and cell-free DNA in ovarian cancer: pathological relevance and diagnostic applications.Extracellular vesicles and circulating nucleic acids · 2026Review
- Precision oncology in gynecologic cancers: molecular taxonomy, biomarker-guided therapeutics, and the challenge of therapeutic resistance.Frontiers in oncology · 2026Review
- Artificial intelligence in ovarian cancer prevention and control: a brief review of detection, treatment, and equity (2021-2026).Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Jamie E Medina *The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-6124-0548
Akshaya V Annapragada *The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-9097-6511
Pien LofDepartment of Gynecologic Oncology, Centre of Gynecologic Oncology Amsterdam, Antoni van Leeuwenhoek Hospital-The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0002-4305-483X
Sarah ShortThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-2319-6360
Adrianna L BartolomucciThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0008-1982-708X
Dimitrios MathiosThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-0792-6880
Shashikant KoulThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-9690-7349
Noushin NiknafsThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-4852-3674
Michaël NoëThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-5336-4508
Zachariah H FodaThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-3591-8482
Daniel C BruhmThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-8436-501X
Carolyn HrubanThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-9882-040X
Nicholas A VulpescuThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-1310-0257
Euihye JungPenn Ovarian Cancer Research Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.ORCID 0000-0003-1202-247X
Renu DuaThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0008-3775-5219
Jenna V CanzonieroThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-1084-6918
Stephen CristianoThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-7375-2364
Vilmos AdleffThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-5001-1766
Heather SymeckoBasser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0009-0008-9257-7953
Daan van den BroekDepartment of Laboratory Medicine, Antoni van Leeuwenhoek Hospital-The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0002-0514-9811
Lori J SokollThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-5130-0060
Stephen B BaylinThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-3697-3798
Michael F PressDepartment of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0003-3400-6614
Dennis J SlamonDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.ORCID 0000-0002-6330-498X
Gottfried E KonecnyDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.ORCID 0000-0001-6083-657X
Christina TherkildsenDepartment of Surgical Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark.ORCID 0000-0002-2833-6986
Beatriz CarvalhoDepartment of Pathology, Antoni van Leeuwenhoek Hospital-The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0003-4903-399X
Gerrit A MeijerDepartment of Pathology, Antoni van Leeuwenhoek Hospital-The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0003-0330-3130
Claus Lindbjerg AndersenDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0002-7406-2103
Susan M DomchekPenn Ovarian Cancer Research Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.ORCID 0000-0002-5914-7272
Ronny DrapkinPenn Ovarian Cancer Research Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.ORCID 0000-0002-6912-6977
Robert B ScharpfThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-4702-2656
Jillian PhallenThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-5492-9013
Christine A R LokDepartment of Gynecologic Oncology, Centre of Gynecologic Oncology Amsterdam, Antoni van Leeuwenhoek Hospital-The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0001-8693-7299
Victor E VelculescuThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-1195-438X
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6MTumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI THOMPSON, ELIZABETH D · 1993 to 2022
$54.6MSPORE in Ovarian CancerP50CA228991 · NCI · JOHNS HOPKINS UNIVERSITY · PI Amanda Nickles Fader · 2018 to 2026
$20.5MMedical Scientist Training ProgramT32GM136577 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI ANDREA L COX · 2020 to 2026
$13.4MECOG-ACRIN Thoracic Malignancies Integrated Translational Science CenterUG1CA233259 · NCI · EMORY UNIVERSITY · PI CARBONE, DAVID P., LEAL, TICIANA · 2019 to 2025
$5.1MLarge-Scale Genetic Analyses of Human CancerR01CA121113 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANAGNOSTOU, VALSAMO, VELCULESCU, VICTOR E. · 2006 to 2022
$4.3MDNA evaluation of fragments for early interception (DELFI) of Lung cancerU01CA271896 · NCI · JOHNS HOPKINS UNIVERSITY · PI DAVID SIDRANSKY, Victor E. Velculescu · 2023 to 2026
$3.8MPredoctoral Training Program in Human GeneticsT32GM148383 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Kimberly F Doheny, ANDREW S MCCALLION · 2023 to 2026
$2.4MGenome-wide approaches to non-invasive screening and characterization of ovarian cancersF30CA294612 · NCI · JOHNS HOPKINS UNIVERSITY · PI Akshaya Vijaya Annapragada · 2024 to 2026
$164kCanary Foundation (THE CANARY FUND)Carl H. Goldsmith Ovarian Cancer Translational Research FundClaneil Foundation (The Claneil Foundation)Cole Foundation (CF)Commonwealth Foundation for Cancer Research FoundationDanish Cancer SocietyDELFI DiagnosticsDr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF) Dr. Miriam and Sheldon G. Adelson Medical Research FoundationGray FoundationHonorable Tina Brozman Foundation (Tina's Wish)Mark Foundation For Cancer Research (The Mark Foundation for Cancer Research)Mike and Patti Hennessy FoundationMonica K. Young FoundationNational Institutes of Health (NIH) CA062924National Institutes of Health (NIH) CA121113National Institutes of Health (NIH) CA228991National Institutes of Health (NIH) F30CA294612National Institutes of Health (NIH) T32GM148383NCI NIH HHS F30 CA294612NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA062924NCI NIH HHS P50 CA228991NCI NIH HHS R01 CA121113NCI NIH HHS U01 CA271896NCI NIH HHS UG1 CA233259NIGMS NIH HHS T32 GM136577NIGMS NIH HHS T32 GM148383Novo Nordisk FoundationStand Up To Cancer (SU2C) SU2C-AACR-DT1415Stand Up To Cancer (SU2C) SU2C in-Time Lung Cancer Interception Dream Team GrantStichting Hanarth FondsU.S. Department of Defense (DOD) DoD Omics Consortium W81XWH-22-1-0852
Abstract
significanceThere is an unmet need for effective ovarian cancer screening and diagnostic approaches that enable earlier-stage cancer detection and increased overall survival. We have developed a high-performing accessible approach that evaluates cfDNA fragmentomes and protein biomarkers to detect ovarian cancer.
Indexed as
Biomarkers, TumorCell-Free Nucleic AcidsEarly Detection of CancerOvarian NeoplasmsFemaleHumansBiomarkers, TumorCell-Free Nucleic Acids
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.